Erratum: Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

被引：0

作者：

M Figus

M Nardi

P Piaggi

M Sartini

G Guidi

L Martini

S Lazzeri

机构：

来源：

Eye | 2014年 / 28卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Correction to: Eye (2014) 28, 422–429; doi:10.1038/eye.2013.304; published online 17 January 2014 Since the publication of the above article, it has been noted that the colour of the lines in Figure 1 were the wrong way round. The correct figure appears below. The authors apologise for this error.

引用

页码：506 / 506

共 50 条

[21] A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%:: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients
Martin, E.
Martinez-de-la-Casa, J. M.
Garcia-Feijoo, J.
Troyano, J.
Larrosa, J. M.
Garcia-Sanchez, J.
EYE, 2007, 21 (02) : 164 - 168
[22] Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
Pillunat, Lutz E.
Eschstruth, Peter
Haesemeyer, Stefan
Thelen, Ulrich
Foja, Christian
Leaback, Richard
Pfennigsdorf, Stefan
CLINICAL OPHTHALMOLOGY, 2016, 10 : 1759 - 1765
[23] A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
Robin, AL
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (06) : 921 - 922
[24] Effect of sustained-release bimatoprost implant (Bimatoprost SR) on visual field mean deviation in glaucoma patients in a phase 1/2 clinical trial
Stalmans, Ingeborg
Bejanian, Marina
Goodkin, Margot
Zhang, Jane
Wang, Kevin
Rivas, Marcos
Robinson, Michael
Rhee, Douglas J.
ACTA OPHTHALMOLOGICA, 2019, 97
[25] A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma
Monte S. Dirks
Robert J. Noecker
Melissa Earl
Shiyoung Roh
Steven M. Silverstein
Robert D. Williams
Advances in Therapy, 2006, 23 : 385 - 394
[26] A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma
Dirks, Monte S.
Noecker, Robert J.
Earl, Melissa
Roh, Shiyoung
Silverstein, Steven M.
Williams, Robert D.
ADVANCES IN THERAPY, 2006, 23 (03) : 385 - 394
[27] An observational study of bimatoprost 0.01% in treatment-naive patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
Nixon, Donald R.
Simonyi, Susan
Bhogal, Meetu
Sigouin, Christopher S.
Crichton, Andrew C.
Discepola, Marino
Hutnik, Cindy M. L.
Yan, David B.
CLINICAL OPHTHALMOLOGY, 2012, 6 : 2097 - 2103
[28] Viscocanalostomy vs trabeculectomy: a 12-month randomized prospective trial.
Carassa, RG
Bettin, P
Fiori, M
Sannace, C
Brancato, R
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S744 - S744
[29] Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical PracticeEffectiveness and Safety of the Bimatoprost ImplantE. Mann et al.
Eric Mann
Jeffrey A. Kammer
Gagan Sawhney
Jella An
Erica C. Werts
Vanessa Vera
Marcos Rivas
Hongxin Lai
Sadhana Sonparote
E. Randy Craven
Drugs, 2025, 85 (3) : 397 - 414
[30] Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
Pfennigsdorf, Stefan
Ramez, Osman
von Kistowski, Gerrit
Maeder, Birgit
Eschstruth, Peter
Froboese, Michael
Thelen, Ulrich
Spraul, Christoph
Schnober, Dietmar
Cooper, Hazel
Laube, Thomas
CLINICAL OPHTHALMOLOGY, 2012, 6 : 739 - 746

← 1 2 3 4 5 →